interaction records 54 assistance programs 55 0 personal data stored

Generic competition · all medicines · read 12 November 2026

Is there a generic of Zilucoplan Sodium, and who makes it?

Zilucoplan Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Zilucoplan Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Zilucoplan Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Zilbrysq. No generic is listed as marketed.

202020252030203501brand 2023data datePatent 11752190 listed to expire 12 June 2035Patent 11014965 listed to expire 12 June 2035Patent 10435438 listed to expire 12 June 2035Patent 10208089 listed to expire 12 June 2035Patent 10106579 listed to expire 12 June 2035Patent 10835574 listed to expire 12 June 2035Patent 11535650 listed to expire 12 June 2035Patent 10562934 listed to expire 12 June 2035Patent 11965040 listed to expire 12 June 2035Exclusivity NCE to 17 October 2028Exclusivity ODE-446 to 17 October 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 October 2028Exclusivity NCE Zilbrysq
  • 17 October 2030Exclusivity ODE-446 Zilbrysq
  • 12 June 2035Patent 11752190 drug product
  • 12 June 2035Patent 11014965 drug substance
  • 12 June 2035Patent 10435438 drug substance
  • 12 June 2035Patent 10208089 drug substance
  • 12 June 2035Patent 10106579 drug substance
  • 12 June 2035Patent 10835574 drug product
  • 12 June 2035Patent 11535650 drug product
  • 12 June 2035Patent 10562934 drug substance

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.